The SOL-1 trial delivered exactly what many in retina had stopped expecting: a clean, FDA-aligned Phase 3 study in wet AMD showing superiority versus an approved anti-VEGF on the gold-standard endpoint of vision loss (<15 letters lost from baseline), with durable anatomic control and no meaningful safety signal from a single AXPAXLI injection.

From a data perspective, the message is straightforward. In newly diagnosed wet AMD patients who responded well to two loading doses of aflibercept 2 mg and were then randomized to a single dose of either AXPAXLI 0.45 mg or aflibercept, 74.1% of patients on AXPAXLI maintained vision through week 36, compared with 55.8% on aflibercept. The statistical separation is robust (risk difference roughly 17–18 percentage points, highly significant p-value) and persists to week 52, where about two-thirds of AXPAXLI-treated patients still maintained vision from that single injection.

On anatomy, which is how retina specialists actually manage patients, the signal is even more striking. Over half of AXPAXLI patients kept central subfield thickness within 30 microns of baseline out to week 36, and close to half did so at week 52. In practice, this means fluid is tightly controlled for many months, not just a few weeks, in a population selected to be difficult (patients expected to lose vision once the loading effect of aflibercept waned).

Safety is the other pillar. Across SOL-1, there were no treatment-related serious ocular or systemic adverse events for AXPAXLI. No cases of occlusive vasculitis, endophthalmitis or other “deal-breaker” safety signals that have derailed other potent retina candidates in the past. Retention to week 52 was very high in both arms, and repeat dosing did not produce obvious new concerns in the available data.

On the tape, however, the reaction has been far less linear. The stock staged a powerful rally into the read-out, exploded higher on the topline press release and call, then suffered a brutal reversal as traders took profits, questioned the control arm, or simply de-risked after a crowded run-up. Subsequent news flow about Macula Society presentations, the upcoming investor webcast and March conferences has stabilised the story but has not removed volatility.

For investors looking beyond the next headline, the picture is more binary but also more structured. If AXPAXLI converts these SOL-1 results into an NDA, a superiority label and broad adoption in fixed-interval dosing regimens, Ocular potentially sits on a multi-year, category-shaping retina franchise. If adoption is slower, payer dynamics tougher or safety signals appear later, the current valuation quickly starts to price in a lot of optimism. The difference between those paths will hinge on three things: the full SOL-1 data at Macula Society, the design and outcome of SOL-R, and real-world retina behaviour once physicians have a chance to use AXPAXLI in practice.

3.1 SOL-R – fixed six-month dosing in a more stable population

SOL-R is the natural sequel to SOL-1. While SOL-1 asked whether a single AXPAXLI treatment could beat a single aflibercept injection in a deliberately tough population, SOL-R tests fixed six-month dosing intervals in patients selected to be more stable and easier to control. Randomisation was completed in December 2025, with topline data now guided for the first quarter of 2027.

Crucially, SOL-R uses a different, more clinically realistic rescue rule (combining modest vision loss with significant CST increase). When these SOL-R criteria were applied retrospectively to the SOL-1 dataset, approximately 80% of AXPAXLI patients would have remained rescue-free at six months, despite the tougher population. It is reasonable – though not guaranteed – to expect equal or better durability in SOL-R, where unstable patients are screened out over a longer pre-randomisation period.

3.2 Diabetic retinal disease and the ELUTYX platform

Beyond wet AMD, AXPAXLI is already being advanced in diabetic retinal disease, including non-proliferative diabetic retinopathy. The same logic applies: if a single injection or infrequent fixed dosing can maintain anatomic control and protect vision without surgery or steroids, the burden on patients, caregivers and retina clinics falls dramatically. Early-stage data in diabetic indications will be critical to assessing whether AXPAXLI can scale beyond wet AMD into a broader retina platform.

Ocular’s ELUTYX hydrogel technology also underpins DEXTENZA (post-surgical inflammation and pain, ocular itching) and the glaucoma candidate OTX-TIC. The company is still evaluating next steps for OTX-TIC, but the key point for the retina story is that AXPAXLI is not a random one-off molecule; it is part of a cohesive, bioresorbable hydrogel delivery platform that has already generated an approved product and several clinical-stage programs.

3.3 Regulatory strategy – 505(b)(2) and the importance of the label

Management has been explicit that, subject to discussions with the FDA, they plan to pursue an NDA for AXPAXLI in wet AMD on the basis of SOL-1, using an accelerated 505(b)(2) pathway. The fact that SOL-1 is a single, well-controlled, SPA-aligned Phase 3 trial with a superiority endpoint gives them a credible argument that the data package is sufficient – especially after full 52-week details are presented at Macula Society and filed via 8-K.

The wording of the final label will matter enormously. A clear, unambiguous superiority claim versus aflibercept 2 mg on a recognised clinical endpoint is a durable commercial moat: it sets a new bar for competitors and gives payers and physicians a simple narrative. If the label ends up more cautious or restricted in scope, the commercial advantage narrows. One of the key things to watch in 2026–2027 will be how regulators choose to phrase and frame that superiority.

Ahead of the SOL-1 read-out, Ocular raised substantial capital, leaving the company with roughly 737 M USD of cash and equivalents at 31 December 2025 and publicly guiding runway “into 2028” on current plans. This is a very different balance-sheet picture from the typical small-cap biotech approaching a binary Phase 3 event with a thin cash cushion.

Revenue today is still modest and comes primarily from DEXTENZA sales. Operating expenses reflect a company that is simultaneously running late-stage retina trials, exploring additional indications and supporting a commercial franchise. The net result is a sizeable annual net loss, as expected for a company at this stage, but one that is currently financed without emergency measures.

The key questions for investors on the financial side are therefore less about survival and more about capital allocation:

• How aggressively will the company invest behind a potential AXPAXLI launch before seeing real-world adoption?
• Will management prioritise keeping optionality for a future partnership or strategic transaction, rather than fully building a large standalone commercial infrastructure in retina?
• How will the company balance spending on HELIOS-3 and possible follow-on trials (such as SOL-X) against the desire to preserve runway and avoid highly dilutive financings at volatile share prices?

With runway into 2028, AXPAXLI has enough financial oxygen to reach NDA submission, regulatory review and initial launch phases without a forced raise. Additional capital raises are still possible – especially if management chooses to lean into expansion opportunities – but they are more a question of strategy than of bare necessity at this stage.

• Regulatory and label risk. AXPAXLI still has to go through full NDA review. Any change in how superiority is framed – or additional requirements for longer follow-up or extra studies – could delay approval or soften the perceived edge.
• Late-emerging safety signals. Even if SOL-1 looks clean at 52 weeks, larger real-world exposure can reveal rare complications. Retina specialists are particularly sensitive to permanent, vision-threatening events.
• Payer constraints and pricing. A highly durable therapy challenges current reimbursement patterns. If payers push hard on prior authorisations, step-edits or lower prices, the adoption curve may flatten.
• Competition. The bar in wet AMD and diabetic disease keeps moving. Other long-acting approaches, delivery technologies or combination regimens may emerge, eroding AXPAXLI’s first-mover advantage even with a superiority claim.
• Execution and focus. Running a late-stage retina franchise, supporting DEXTENZA, advancing HELIOS-3 and managing a large balance sheet all at once creates execution risk. Strategic discipline will matter as much as the data.
• Market expectations. After the recent run-up and violent volatility around the read-out, expectations are not low. Any perceived “disappointment” in Macula Society slides, NDA interactions or early adoption could trigger outsized moves.

• Macula Society slide deck. Level of detail on anatomic endpoints, rescue-free curves and subgroup analyses; any nuances in patients who needed early rescue or developed concerning findings.
• Formal interactions with the FDA. Clarity on whether SOL-1 is sufficient as a single pivotal trial, and on the anticipated structure and timing of the NDA.
• Language in the eventual label. How explicitly superiority versus aflibercept is stated, and whether any specific limitations or warnings are emphasised.
• SOL-R operational updates. Confirmation that the study remains on track for a 1Q 2027 topline read-out, with no unexpected protocol changes.
• Helios-3 progress. Early signals that AXPAXLI-style durability can extend to diabetic retinal disease would support the broader platform thesis.
• Real-world feedback post-approval. Even anecdotal reports from early adopters on durability, ease of use and patient satisfaction will matter for the adoption curve.
• Balance-sheet discipline. How management uses the current cash position, particularly in terms of launch build-out versus preserving optionality for partnerships.